Intervacc is trading 12.98% down at €0.08 after the August 6, 2026 session, with no fresh company-specific negative announcement identified.
- Recent disclosures were generally constructive: an EMA application was submitted on July 30, 2026, seeking 12-month Strangvac immunity, and New Zealand access was announced under a special permit.
- The decline remains unexplained by available company news despite biotechnology sector strength, appearing more consistent with thin-liquidity trading or stock-specific selling than broad sector weakness.